Cancer BiologybioRxivPreprint
Tipifarnib potentiates the antitumor effects of PI3Kα inhibition in PIK3CA- and HRAS-dysregulated HNSCC via convergent inhibition of mTOR activity
A. E. Smith, S. Chan, Z. Wang…·S. Malik
This study combines tipifarnib and alpelisib to target PI3K-mTOR and HRAS in HNSCC, showing synergy in mTOR inhibition and clinical potential for R/M HNSCC patients.
DOI 10.1101/2023.01.17.523964